Exon-1 polymorphism of ctla-4 gene is not associated with systemic sclerosis in Iranian patients

Rheumatology International

Volumn 26, Issue 8, 2006, Pages 687-692

  Rajaee, A ^a   Ebrahimi, A ^a   Ghiam, A Fotouhi ^c   Kalantari, T ^b   Ghaderi, A ^b,c  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

CTLA 4; Polymorphism; Systemic sclerosis

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GENOMIC DNA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; EXON; FEMALE; GENE AMPLIFICATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; SYSTEMIC SCLEROSIS;

ADULT; AGE OF ONSET; ALLELES; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; CASE-CONTROL STUDIES; EXONS; FEMALE; GENE FREQUENCY; HUMANS; IRAN; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; SCLERODERMA, SYSTEMIC;

EID: 33646549575     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-005-0047-6     Document Type: Article

References (31)

1. Zhou X, Tan FK, Wang N, Xiong M, Maghidman S, Reveille JD et al (2003) Genome-wide association study for regions of systemic sclerosis susceptibility in a Choctaw Indian population with high disease prevalence. Arthrit Rheum 48:2585-2592
2. Derk CT, Jimenez SA (2003) Systemic sclerosis: current views of its pathogenesis. Autoimmun Rev 2:181-191
3. Bitterncourt PL, Palacios SA, Cancado ELR, Porta G, Carrilho FJ et al (2003) Cytotoxic T lymphocyte antigen-4 gene polymorphism do not confer susceptibility to Autoimmune Hepatitis type 1 and 2 In Brazil. Am J Gastroenterol 98:1616-1620
4. Mayes MD (2003) Scleroderma epidemiology. Rheum Dis Clin North Am 29: 239-254
5. Atamas, White SP, Barbara (2003) The role of chemokines in the pathogenesis of scleroderma. Cur Opin Rheumatol 15: 772-777
6. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K (1997) Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. Rheumatol 24:328-332
7. Takagi K, Kawaguchi Y, Hara M, Sugiura T, Harigai M, Kamatani N (2003) Serum nitric oxide (NO) levels in systemic sclerosis patients: correlation between NO levels and clinical features. Clin Exp Immunol 134:538-544
8. Neudecker BA, Stern R, Connolly MK (2004) Aberrant serum hyaluronan and hyaluronidase levels in scleroderma. Dermatol 150:469-476
9. Kessel A, Rosner I, Rozenbaum M, Zisman D, Sagiv A, Shmuel Z et al (2004) Increased CD8+ T cell apoptosis in scleroderma is associated with low levels of NF-kappaB. J Clin Immunol 24:30-36
10. Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K (2004) Increased expression levels of integrin alphavbeta5 on scleroderma fibroblasts. Am J Pathol 164:1275-1292
11. Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K (2004) Impaired Smad7-smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts. J Clin Invest 113:253-264
12. Chung L, Utz PJ (2004) Antibodies in scleroderma: direct pathogenicity and phenotypic association. Curr Rheumatol Rep 6:156-163
13. Tan FK (2004) Systemic sclerosis: the susceptible host (genetics and environment). Rheum Dis Clin North Am 29:211-237
14. Tikly M, Rands A, McHugh N, Wordsworth P, Welsh K (2004) Human leukocyte antigen class II associations with systemic sclerosis in South Africans. Tissue Antigens 63:487-490
15. Chistiakov DA, Turakulov RI (2003) CTLA-4 and its role in autoimmune thyroid disease (Review). J Mol Endocrinol 31:21-36
16. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G et al (2003) Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423:506-511
17. Steen VD, Medsger TA Jr (1990) Epidemiology and natural history of systemic sclerosis. Rheum Dis Clin North Am 16:1-10
18. Kalantari T, Mostafavi H, Pezeshki AM, Farjadian S, Doroudchi M, Yeganeh F, Ghaderi A (2003) Exon-1 polymorphism of ctla-4 gene in Iranian patients with Graves' disease. Autoimmunity 36:313-316
19. Donner H, Braun J, Seidl C, Rau H, Finke R, Ventz M et al (1997) Codon 17 polymorphism of the cytotoxic T lymphocyte antigen 4 gene in Hashimoto's thyroiditis and Addison's disease. J Clin Endocrinol 82:4130-4132
20. Gintrac M (1847) Note sur la sclerodermie. Rev Med Chir Paris 2:263-281
21. Rodnan GP, Benedek TG (1962) A historical account of the study of progressive systemic sclerosis (diffuse scleroderma). Ann Intern Med 57: 305-319
22. Herrick AL, Worthington J (2002) Genetic epidemiology: systemic sclerosis. Arthritis Res 4:165-168
23. Simmonds MJ, Gough SCL (2004) Unravelling the genetic complexity of autoimmune thyroid disease: HLA, CTLA-4 and beyond. Clin Experiment Immunol 136:1
24. Kouki T, Sawai Y, Gardine CA, Fisfalen ME, Alegre ML, DeGroot LJ (2000) CTLA-4 gene polymorphism at position 40 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol 165:6606-6611
25. Hudson LL, Silver RM, Pandey JP (2004) Ethnic differences in cytotoxic T lymphocyte associated antigen-4 genotype association with systemic sclerosis. Rheumatol 31:85-87
26. Takeuchi F, Kawasugi K, Nabeta H, Mori M, Tanimoto K (2002) Association of CTLA-4 with systemic sclerosis in Japanese patients. Clin Exp Rheumatol 20:823-828
27. Ghaderi A, Yeganeh F, Kalantari T, Talei AR, Pezeshki AM, Doroudchi M, Samsami DA (2004) Cytotoxic T lymphocyte antigen-4 in breast cancer. Breast Cancer Res Treat 86:1-7
28. Ligers A, Teleshova N, Masterman T, Huang WX, Hillert J (2001) CTLA-4 gene expression in influenced by promoter and exon 1 polymorphism. Genes Immun 2:145-152
29. Hill CL, Nguyen AM, Roder D, Roberts-Thomson P (2003) Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis 62:728-731
30. De Angelis R, Bugatti L, Cerioni A, Del Medico P, Filosa G (2003) Diffuse scleroderma occurring after the use of paclitaxel for ovarian cancer. Clin Rheumatol 22:49-52
31. Bachleitner-Hofmann T, Machold K, Knobler R, Drach J, Grumbeck E, Gisslinger H (2002) Marked and sustained improvement of systemic sclerosis following polychemotherapy for coexistent multiple myeloma. Clin Exp Rheumatol 20:85-88